Know more

Our use of cookies

Cookies are a set of data stored on a user’s device when the user browses a web site. The data is in a file containing an ID number, the name of the server which deposited it and, in some cases, an expiry date. We use cookies to record information about your visit, language of preference, and other parameters on the site in order to optimise your next visit and make the site even more useful to you.

To improve your experience, we use cookies to store certain browsing information and provide secure navigation, and to collect statistics with a view to improve the site’s features. For a complete list of the cookies we use, download “Ghostery”, a free plug-in for browsers which can detect, and, in some cases, block cookies.

Ghostery is available here for free:

You can also visit the CNIL web site for instructions on how to configure your browser to manage cookie storage on your device.

In the case of third-party advertising cookies, you can also visit the following site:, offered by digital advertising professionals within the European Digital Advertising Alliance (EDAA). From the site, you can deny or accept the cookies used by advertising professionals who are members.

It is also possible to block certain third-party cookies directly via publishers:

Cookie type

Means of blocking

Analytical and performance cookies

Google Analytics

Targeted advertising cookies


The following types of cookies may be used on our websites:

Mandatory cookies

Functional cookies

Social media and advertising cookies

These cookies are needed to ensure the proper functioning of the site and cannot be disabled. They help ensure a secure connection and the basic availability of our website.

These cookies allow us to analyse site use in order to measure and optimise performance. They allow us to store your sign-in information and display the different components of our website in a more coherent way.

These cookies are used by advertising agencies such as Google and by social media sites such as LinkedIn and Facebook. Among other things, they allow pages to be shared on social media, the posting of comments, and the publication (on our site or elsewhere) of ads that reflect your centres of interest.

Our EZPublish content management system (CMS) uses CAS and PHP session cookies and the New Relic cookie for monitoring purposes (IP, response times).

These cookies are deleted at the end of the browsing session (when you log off or close your browser window)

Our EZPublish content management system (CMS) uses the XiTi cookie to measure traffic. Our service provider is AT Internet. This company stores data (IPs, date and time of access, length of the visit and pages viewed) for six months.

Our EZPublish content management system (CMS) does not use this type of cookie.

For more information about the cookies we use, contact INRA’s Data Protection Officer by email at or by post at:

24, chemin de Borde Rouge –Auzeville – CS52627
31326 Castanet Tolosan CEDEX - France

Dernière mise à jour : Mai 2018

Menu INRA Logo partenaire

Home page

Development of new technologies for biobanking

Development of new technologies for biobanking
All CRB-Anim activities will increase the knowledge on cryobanking and could result on new technologies

The IMV company (Instruments de Médecine Vétérinaire, L’Aigle, France) is the only French company to be a major player worldwide in the field of cryoconservation of gametes and embryos, and thus is a preferential partner of CRB-Anim for cryobanking. For instance, IMV has an exclusive license on the INRA patent for semen diluents in horses, with an annual return of 300 k€ since 10 years. IMV had 250 collaborators and a budget turnover of 48 M€ each year with 80% exports to 120 countries, but 95% of the manufacturing takes place in France. The IMV group counts 5 daughter companies in Europe (Italy, Netherlands) USA, China and India. INRA and IMV have already negotiated preferential prices for consumables used for cryobanking. IMV will be contacted first for licensing technological innovations developed within CRB-Anim. Even for niche market such as aquatic species, IMV agreed to render the extenders available to the aquatic community on a request basis.

Technology transfer and marketing will include diluents, synthetic media, and procedures for all species where cryoconservation is not yet operational (particularly aquaculture species, quail and donkey) or not optimal (other birds). Training of the IMV staff is already planned for aquaculture species. IMV has agreed to sell these products under a license contract between the partners, as done previously. Procedures for embryo freezing in horses are also needed, with an expected saving of 50% of the total costs (1.2 M€) of embryo transfer in horses and a boosting effect on exports. A horse embryo is sold about 4 k€.

The developments dealing with somatic cells, pluripotent stem cells, iPS could result in patenting new procedures. New quality control procedures for biological samples are expected from the technological developments of CRB-Anim, that could be developed in partnership with biotech companies such as IMAGENE, IntegraGen. INRA platforms may also consider direct exploitation of new procedures.